Metformin, the first line drug for Type 2 diabetes, has been used for 60 years without a clearcut mechanism of action. It turns out it's not just reducing glucose output from the liver. Metformin also works via the brain science.org/doi/10.1126/sc…

Online Now: Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer dlvr.it/TMDVl8

🚨Online today: Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant #prostatecancer in #ENZAp (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial thelancet.com/journals/lanon…

📝 Final analysis of GAIA/CLL13 trial presented by Arnon Kater at #EHA2025 found that 5-year PFS rates were highest for GIV vs GV, RV, and CIT (81.3% vs 69.8%, 57.4% and 50.7%) in treatment-naïve patients with CLL. More news: LymphomaHub.com #lymphoma #lymsm #MedNews

🚨 Lace up, Berlin! Join us for the #OncoAlert5K at #ESMO25 🏃‍♂️🏃‍♀️ 🗓️ Saturday, October 18 – 7:00 AM 📍 Brandenburg Gate 🇩🇪 Start your day with fresh air, good vibes & great company before the science takes over! 👟 Sign-up coming soon!

🥁The most updated epidemiology data in #kidneycancer 👇 doi.org/10.1016/j.euru… OncoAlert European Urology

Happy to share our recent publication in #CLML exploring the role of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in #MDS Moffitt Cancer Center Faiz Anwer MD clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

Sing it loud! 🐉

Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection*) is now listed on the Medicare Benefits Schedule in Australia for selection of patients’ suitability for lutetium-177 PSMA therapy. Swipe to hear from Anne Savage, CEO of the Prostate Cancer Foundation of Australia

Cancer cachexia! More than weight loss, it’s losing strength. We need action, research, and empathy for every patient! Cancer Discovery AACR OncoAlert Oncology Brothers Elizabeth McKenna #cancer #cachexia #Oncology doi: 10.1158/2159-8290.CD-25-0293

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn — Click the image below to read more! || #MedTech Insights | Start your free trial today: vist.ly/32ner vist.ly/32nes

Controversies in metastatic hormone-sensitive prostate cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Metastatic hormone-sensitive #ProstateCancer (mHSPC) remains incurable, but advances in diagnostics and treatment are expanding management options. This review examines four key controversies:

☑️#WCLC25 #LCSM Oral🆙 🔥DeLLphi-303 🔥Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial 🎙️ Dr. Kelly Paulson OncoAlert LARVOL IASLC cattendee.abstractsonline.com/meeting/21151/…

Are the overall response and individual lesion responses of patients with #mCRPC dependent on the absorbed dose of ¹⁷⁷Lu-PSMA-617 radiopharmaceutical therapy? ow.ly/xWrQ50WGwzo #RPTherapy #NuclearMedicine @LisaBodei @Simoneskrebs

Part 1/3 on SCLC! Here we discuss the treatment landscape and the data from #ASCO25 in Extensive Stage small cell w/ Hossein Borghaei, DO Full 📢 🌟 gotoper.com/courses/breaki… 🌟 oncbrothers.com/sclc-cme-2025-1 🌟Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #lcsm #CME

This is the algorithm for reference during our discussion with Hossein Borghaei, DO during our discussion on #SmallCellLungCancer! #OncTwitter #MedTwitter #lcsm

Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials jamanetwork.com/journals/jaman… This cohort study analyzed individual patient data from the SPARTAN and TITAN phase 3 trials to examine the impact of statin exposure on outcomes in men with advanced

Cisplatin saves lives, but kidneys pay a price. 🔘1 in 7 pts develop Chronic Kidney Disease After Cisplatin Treatment. Baseline eGFR is the strongest predictor, check it, discuss risks, hydrate, avoid nephrotoxins. #Nephrology #Oncology JAMA Oncology OncoAlert Oncology Brothers Uromigos

Cisplatin-ineligible MIBC: no more exclusion from neoadjuvant therapy! 👏👏👏 SunRISe-4 (TAR-200+cetrelimab, 42% pCR) and EV-303 (EV+pembro) bring real promise for this population. #bladdercancer #oncology OncoAlert Andrea Necchi Andrea Apolo, M.D. Tom Powles Syed A Hussain

¡Qué buenas noticias! Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved in Spain. Access to PSMA-PET imaging in Spain has been limited by the low number of clinical sites with gallium generators, especially in regional areas. With